Novel, potent androgen receptor (AR) pathway inhibitors (ARPIs) such as enzalutamide (enza), abiraterone, apalutamide, and darolutamide are commonly used in the treatment of men with prostate cancer. Here, AR is linked to prostate carcinoma.